Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years-Reference-Cited by-同舟云学术

Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

Published:2020-08-05 Issue:13 Volume:61 Page:3120-3127
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Major Catherine Kendall¹^ORCID,Kantarjian Hagop²,Sasaki Koji²,Borthakur Gautam²^ORCID,Kadia Tapan²,Pemmaraju Naveen²,DiNardo Courtney²,Short Nicholas J.²,Daver Naval²,Jabbour Elias²,Champlin Richard²,Garcia-Manero Guillermo²,Konopleva Marina²,Andreeff Michael²,Kornblau Steven²,Wierda William²,Pierce Sherry²,Ravandi Farhad²,Cortes Jorge³^ORCID

Affiliation:

1. Eastern Virginia Medical School, Norfolk, VA, USA

2. Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA

3. Georgia Cancer Center, Augusta University, Augusta, GA, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1802450

Reference29 articles.

1. Cancer statistics, 2020